Title Semaglutide: will weight-loss drugs solve the obesity crisis? Media name/outlet Institute for Optimum Nutrition Country/Territory United Kingdom Date 18/12/23 Description Semaglutide is the active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy - both of which have made headlines for their effectiveness helping people lose weight. But their widespread use may make diet and lifestyle medicine more needed than ever. Hatty Willmoth writes.
Ozempic, Wegovy and other weight-loss medications are arguably the biggest health story of 2023: drugs that might solve the obesity crisis now available on the NHS.
Semaglutide, the active ingredient in Ozempic and Wegovy, is apparently ubiquitous in the celebrity world and apparently lifesaving for those for whom it has been developed.
With Mounjaro on the way in 2024 – a similar drug, using tirzepatide, that’s supposedly even more powerful – a revolution seems underway, one where obesity has been conquered by pharmaceuticals once and for all.
But it might not be that simple. And, as these drugs become more widespread, nutrition and lifestyle specialists may be more needed than ever.
In this article, Dr Natascha Van Zyl talks about the use of Semaglutide, its side effects and the considerations for a long-term approach to sustained weight loss.
Producer/Author Hatty Willmoth URL https://www.ion.ac.uk/news/semaglutide Persons Tasch Van Zyl
- Psychological wellbeing
- Weight stigma
- Food quality